Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and racial predictors of adverse pathology at radical prostatectomy: implications for undertreatment among patients receiving radiation and hormonal therapy.

The Canadian journal of urology·2026
Same author

Postoperative Pelvic Lymph Node Radiation Therapy in Lymph Node-Positive Prostate Cancer and Mortality Risk.

European urology focus·2026
Same author

Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high-risk prostate cancer: A predictive biomarker analysis.

Cancer·2026
Same author

Surveillance Versus Treatment for Favorable Intermediate-Risk Prostate Cancer and Mortality-Risk.

The Prostate·2026
Same author

Cribriform-Positive and -Negative Prostate Cancer.

JAMA oncology·2026
Same author

Re: Alexander B.C.D. Ng, Aqua Asif, Ridhi Agarwal, et al. Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial. JAMA 2025;334:1170-9.

European urology·2025

Related Experiment Video

Updated: Jan 3, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K

Radiation Therapy for Prostate Cancer.

Sophia C Kamran1, Anthony V D'Amico2

  • 1Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street-Cox 3, Boston, MA 02114, USA.

Hematology/Oncology Clinics of North America
|November 20, 2019
PubMed
Summary
This summary is machine-generated.

Recent advances in prostate cancer management, including new technologies and targeted therapies, are improving outcomes for nonmetastatic and oligometastatic disease. These innovations enhance cancer control and quality of life for patients.

Keywords:
Androgen deprivation therapyBrachytherapyHypofractionationLocalized prostate cancerOligometastatic prostate cancerPostprostatectomy adjuvant and salvage therapyRadiation therapy

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

593
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Related Experiment Videos

Last Updated: Jan 3, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

593
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urology

Background:

  • Randomized controlled trials (RCTs) guide clinical decisions for nonmetastatic and oligometastatic prostate cancer.
  • Technological advancements are transforming prostate cancer diagnosis and treatment.
  • Radiotherapy shows promise for new indications, especially in oligometastatic prostate cancer.

Purpose of the Study:

  • To review current evidence-based management strategies for prostate cancer.
  • To highlight technological advancements in prostate cancer diagnosis and treatment.
  • To discuss the evolving role of radiotherapy and targeted agents in improving patient outcomes.

Main Methods:

  • Review of randomized controlled trials.
  • Discussion of technological advancements in imaging and treatment delivery.
  • Overview of ongoing clinical studies with next-generation agents.

Main Results:

  • Multiparametric MRI, fusion biopsy, and image-guided radiation therapy improve cancer control and quality of life.
  • Stereotactic body radiation therapy is a key advancement.
  • Next-generation androgen receptor-targeted agents show promise for improved survival and quality of life.

Conclusions:

  • Evidence-based strategies and technological innovations are crucial for managing prostate cancer.
  • Radiotherapy and targeted therapies offer significant potential for improving patient outcomes.
  • Ongoing research is expected to further enhance metastasis-free survival, prostate cancer-specific survival, and overall survival.